Human TAF1 DNA gives mice fatal XDP within two months
Two Cell studies link the rare movement disorder to an SVA insertion that lowers TAF1 and to myelin-making glial cells, and show that raising TAF1 can keep engineered stem cells alive. The illness mainly hits men of Filipino descent and has no cure.
An NYU Langone Health-led team used genome writing to place a 78-kilobase stretch of patient TAF1 DNA into mice, building a model of X-linked dystonia-parkinsonism (XDP). Males carrying the humanized gene died within two months. In people, symptoms of this rare disorder can take roughly 30 years to appear, and the illness mainly affects men of Filipino descent.
The group replaced a section of mouse Taf1 with the matching human sequence, including a disease-causing SVA retrotransposon (SINE-VNTR-Alu). Those elements occur in humans and are missing from mice, so ordinary mouse lines have been a weak way to study them. In embryonic stem cells, the SVA sitting inside the gene, rather than the composite gene around it, cut TAF1 messenger RNA. Chromatin and transcriptome work indicated the insertion is copied into RNA and may form a barrier that halts that copying early, which drops TAF1 and sets off cell death. With the humanized allele active in the nervous system, the animals developed severe atrophy focused on the striatum, the movement-control region also damaged in patients.
Myelin-making cells
A companion Cell paper that used the same mice implicates oligodendrocytes, glial cells that wrap axons in myelin, and not neurons by themselves. The researchers also found myelin loss in stored human XDP brain tissue, a change earlier studies reportedly missed. Shane Liddelow, an associate professor in the Institute for Translational Neuroscience at NYU Grossman School of Medicine, said that pattern “had never been described” in this disease and that it upended the view of XDP as chiefly a neuronal illness. Symptoms on average start around age 39 and include slowed movement, tremor, muscle stiffness and involuntary contractions. Patients live another 13 to 16 years after onset. In late disease, trouble breathing and swallowing can lead to malnutrition, aspiration pneumonia and respiratory failure.
A path toward treatment ideas
Both papers appeared in Cell on Nov. 19. In the engineered stem cells, CRISPR activation that raised TAF1 brought survival back, which the team treats as a reason to explore stronger TAF1 transcription as a therapy. Senior author Jef D. Boeke, director of NYU Langone’s Institute for Systems Genetics and a lead developer of the SwAP-In technique, said the experiments support future treatments for people with XDP. SwAP-In rewrites long spans of an animal’s genetic code by adding sizable pieces of synthetic DNA. Boeke called it a general way to produce mice with extensively humanized DNA, and Liddelow expects it to help research on Alzheimer’s and on rare conditions that still lack effective treatments.